US2012076733A1PendingUtilityA1

Post-biopsy cavity treatment implants and methods

56
Individually held — no corporate assignee on recordPriority: Jul 25, 2003Filed: Dec 1, 2011Published: Mar 29, 2012
Est. expiryJul 25, 2023(expired)· nominal 20-yr term from priority
Inventors:Ary S. ChernomorskyJames W. VetterSimon Chernomorsky
A61L 31/18A61B 17/0057A61B 2090/3908A61B 2090/3987A61K 49/04A61P 17/02A61B 2090/3925A61L 31/146A61B 90/39A61B 2017/00654
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Claims

exact text as granted — not AI-modified
1 . A post-biopsy cavity treatment implant, comprising:
 a radiopaque element;   a core portion coupled to the radiopaque element, the core portion including a first porous matrix defining a first controlled pore architecture, and   a shell portion coupled to the core portion, the shell portion including a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.   
     
     
         2 . The post-biopsy cavity treatment implant of  claim 1 , wherein the core portion surrounds the radiopaque element. 
     
     
         3 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion surrounds the core portion. 
     
     
         4 . The post-biopsy cavity treatment implant of  claim 1 , wherein the core portion surrounds the radiopaque element and the shell portion surrounds the core portion. 
     
     
         5 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion swells faster than the core portion when the implant is placed in a biological fluid environment. 
     
     
         6 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion swells to a greater extent than the core portion when the implant is placed in the biological fluid environment. 
     
     
         7 . The post-biopsy cavity treatment implant of  claim 1 , wherein the first controlled pore architecture differs from the second controlled pore architecture with respect to at least one of: pore density, pore shape, pore orientation and pore dimensions. 
     
     
         8 . The post-biopsy cavity treatment implant of  claim 1 , wherein the radiopaque element includes a portion having a paramagnetic property. 
     
     
         9 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least one of the core and shell portions includes a dye disposed therein. 
     
     
         10 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least one of the core and shell portions includes a pigment disposed therein. 
     
     
         11 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least one of the core and shell portions includes a contrast medium disposed therein. 
     
     
         12 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least one of the core and shell portions includes a therapeutic agent disposed therein. 
     
     
         13 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least one of the core and shell portions is biodegradable. 
     
     
         14 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least the shell portion includes collagen. 
     
     
         15 . The post-biopsy cavity treatment implant of  claim 1 , wherein the core portion includes at least one of a polylactide (PLA), a polyglycolide (PGA), a poly(lactide-co-glycolide) (PLGA), a polyglyconate, a polyanhydride, PEG, cellulose, a gelatin, a lipid, a polysaccharide, a starch and a polyorthoester. 
     
     
         16 . The post-biopsy cavity treatment implant of  claim 1 , wherein the core and shell portions are configured so as to form a laminar structure. 
     
     
         17 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least one of the core and shell portions is echogenic. 
     
     
         18 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least the shell portion includes a plurality of fibers. 
     
     
         19 . The post-biopsy cavity treatment implant of  claim 1 , wherein at least one of the core and shell portions includes an internal reservoir configured to contain at least one of a dye, a pigment and a therapeutic agent. 
     
     
         20 . The post-biopsy cavity treatment implant of  claim 19 , wherein the internal reservoir is configured to deliver the at least one of dye, pigment and therapeutic agent through elution when the implant is placed in a biological fluid environment. 
     
     
         21 . The post-biopsy cavity treatment implant of  claim 19 , wherein the internal reservoir is configured to deliver the at least one of dye, pigment and therapeutic agent at a first rate when the reservoir is breached and at a second rate that is lower than the first rate when the reservoir is not breached. 
     
     
         22 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion is configured to swell to a greater degree than the core portion when the implant is placed in the biological fluid environment. 
     
     
         23 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion includes collagen and wherein a crosslinking density of the shell portion is controlled through adding a selected amount of a bifunctional reagent to the collagen. 
     
     
         24 . The post-biopsy cavity treatment implant of  claim 23 , wherein the bifunctional reagent includes at least one of an aldehyde and a cyanamide. 
     
     
         25 . The post-biopsy cavity treatment implant of  claim 24 , wherein the aldehyde includes a glutaraldehyde. 
     
     
         26 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion include collagen and wherein a crosslinking density of the shell portion is controlled by an application of energy to the collagen. 
     
     
         27 . The post-biopsy cavity treatment implant of  claim 26 , wherein the application of energy includes at least one of dehydrothermal processing, exposure to UV light and radiation. 
     
     
         28 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion includes collagen and wherein a crosslinking density of the shell portion is controlled by a combination of dehydrothermal processing and exposure to cyanamide. 
     
     
         29 . The post-biopsy cavity treatment implant of  claim 1 , wherein the implant, in a state prior to being placed in a biological fluid environment, is generally wedge-shaped. 
     
     
         30 . The post-biopsy cavity treatment implant of  claim 1 , wherein the implant, in a state prior to being placed in a biological fluid environment, has a shape of a disk that has been folded multiple times. 
     
     
         31 . The post-biopsy cavity treatment implant of  claim 1 , wherein the implant, in a state prior to being placed in a biological fluid environment, has a rectangular shape. 
     
     
         32 . The post-biopsy cavity treatment implant of  claim 1 , wherein the shell portion defines a center portion and a peripheral portion and wherein the peripheral portion defines a plurality of independently movable free ends. 
     
     
         33 - 62 . (canceled)

Join the waitlist — get patent alerts

Track US2012076733A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.